drugset / Trial / NCT03886311
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
Timeline
- Start
- 2019-05-15
- Primary completion
- 2030-12-31
- Completion
- 2031-07-31
Publications
- Background Gordon EM, Sankhala KK, Chawla N, Chawla SP. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives. Adv Ther. 2016 Jul;33(7):1055-71. doi: 10.1007/s12325-016-0344-3. Epub 2016 May 27.
- Results Chawla SP, Sankhala KK, Ravicz J, Kang G, Liu S, Stumpf N, Leong B, Kim S, Arasheben S, Tseng WW, Gordon EM. Clinical experience with combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma. J Sarcoma Res. 2018; 2(1):1009.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Talimogene Laherparepvec | Other / unclassified | — | Intrathecal |
| Subject | Trabectedin | Small molecule | 1.2 mg/m2 | Intravenous |